Items tagged “oncology”
187 results found
Article
CEA
Serum CEA (carcinoembryonic antigen) is a cell-adhesive glycoprotein that was discovered in colorectal cancer in 1965, and is hence one of the oldest and most used tumor markers. Its name derives from its normal expression in fetoembryonic liver, gut and pancreas tissue.
Normal range of CEA is ...
Article
Indium-111 OncoScint
Indium-111 OncoScint is a radiopharmaceutical used in SPECT imaging. It is a labeled monoclonal antibody that is directed against TAG-72, which is a tumor-associated antigen associated with ~95% of colorectal carcinomas and 100% of ovarian carcinomas 1,2. Background hepatic uptake limits sensiti...
Article
Pancreatic mesenchymal neoplasms
Pancreatic mesenchymal neoplasms, or pancreatic nonepithelial neoplasms, are a group of rare pancreatic neoplasms that arise from the structural elements of the pancreas (nerves, fat, lymph), rather than from the exocrine or endocrine cells of the pancreas. Neoplasms from exocrine and endocrine ...
Article
Prostate specific antigen
Prostate specific antigen (PSA) is currently used as a tumor marker for prostate adenocarcinoma.
PSA is a 33 kilodalton glycoprotein produced in prostate epithelial cells. Its normal physiologic role is as a liquefying agent for seminal fluid; only a tiny amount leaks into the blood, therefore ...
Article
Primary urethral cancer
Primary urethral cancer, in most cases a urethral carcinoma, is a rare urological malignancy. It can be divided into female urethral cancer and male urethral cancer.
Epidemiology
It has an incidence of 4.3 per million for males and 1.5 per million for females. It usually manifests in the 5th d...
Article
Hand-foot syndrome (chemotherapy)
Hand-foot syndrome, also known as palmar-plantar erythrodysaesthesia or Burgdorf reaction, is a benign, aseptic, self-limiting complication of many chemotherapeutic agents characterized by a widespread erythema, edema and ulceration of the hands and feet.
Causative drugs
Many chemotherapeutic...
Article
Yttrium-90 ibritumomab tiuxetan
Yttrium-90 ibritumomab tiuxetan, also known by the trade name Zevalin (Acrotech Biopharma LLC, USA), is a theranostic radiopharmaceutical approved for the treatment of patients with relapsed or refractory low grade or follicular non-Hodgkin lymphoma (NHL). More specifically, it is a radioimmunot...